| Literature DB >> 35921502 |
Lewis A Lipsitz1,2, Cyrus Kosar3, Alyssa B Dufour1,2, Thomas G Travison1,2, Vincent Mor3,4.
Abstract
BACKGROUND: During the deadly 2020 SARS-CoV-2 surge in nursing homes (NHs), Massachusetts (MA) initiated a multicomponent infection control intervention to mitigate its spread.Entities:
Keywords: COVID-19 intervention; SARS-CoV-2; infection control; long-term care; public health
Year: 2022 PMID: 35921502 PMCID: PMC9538002 DOI: 10.1111/jgs.17984
Source DB: PubMed Journal: J Am Geriatr Soc ISSN: 0002-8614 Impact factor: 7.538
Characteristics of nursing home residents by state at baseline (week 1) and during follow‐up
| Baseline characteristic, mean (SD) or % | Massachusetts | Comparator states |
|---|---|---|
|
|
| |
| Age | ||
| <65 | 7 | 11 |
| 65–69 | 7 | 9 |
| 70–74 | 11 | 12 |
| 75–79 | 13 | 13 |
| 80–84 | 14 | 15 |
| 85–89 | 18 | 17 |
| ≥90 | 30 | 23 |
| Female sex | 67 | 63 |
| Race | ||
| White | 87 | 87 |
| Black | 4 | 6 |
| Hispanic/Other | 9 | 6 |
| ADL summary score (0–28, higher is worse) | 17.3 (5.2) | 15.6 (7.1) |
| ADL quartile | ||
| 1 (0–13) | 17 | 31 |
| 2 (14–18) | 32 | 26 |
| 3 (19–20) | 32 | 19 |
| 4 (21–28) | 20 | 24 |
| Dementia | 53 | 48 |
| Congestive heart failure | 27 | 23 |
| Coronary artery disease | 21 | 22 |
| Asthma/COPD | 26 | 27 |
| Chronic kidney disease | 28 | 28 |
| Hypertension | 80 | 76 |
| Diabetes | 36 | 37 |
| Post‐acute patient | 19 | 21 |
| County SARS‐CoV‐2 prevalence during April, 2020 (per 100,000) | 134.4 (124.4) | 46.0 (80.3) |
| Follow‐up | ||
| Mean/Median weeks of follow‐up | 14/20 | 16/20 |
| % followed for 20 weeks | 57 | 75 |
| All‐cause deaths during study period (number [%]) | 212 (9.7) | 417 (10.2) |
Note: Comparator states include New Hampshire, Rhode Island, and Connecticut.
Abbreviations: ADL, activities of daily living; COPD, chronic obstructive pulmonary disease; chronic kidney disease includes renal insufficiency, renal disease, or end‐stage renal disease.
Baseline characteristics of nursing facilities by state
| Characteristic, median (iqr) or % | Massachusetts | Comparator states |
|---|---|---|
|
|
| |
| Facility size | ||
| Small (0–59 beds) | 0 | 7 |
| Medium (60–120 beds) | 15 | 36 |
| Large (beds >120) | 85 | 58 |
| Total beds | 124 (123–146) | 108 (82–146) |
| % Residents financed by Medicare | 10 (6–14) | 14 (10–22) |
| % Residents financed by Medicaid | 59 (51–66) | 67 (56–75) |
| % Residents financed privately | 30 (20–37) | 17 (12–22) |
| Overall star‐rating (1–5, lower worse) | 3 (2–4) | 3 (2–4) |
| Staffing star‐rating (1–5, lower worse) | 3 (3–4) | 3 (3–4) |
| Infection control citation | 25 | 23 |
| Rural | 0 | 29 |
Note: Comparator states include New Hampshire, Rhode Island, and Connecticut.
Based on whether an infection control citation (F880) was recorded on Medicare's care compare website during 2019.
Rurality was defined using rural–urban continuum codes developed by the US department of agriculture.
Discrete time proportional hazards regression results
| Variable | Risk Ratio (95% CI) |
|
|---|---|---|
| MA versus comparator states, baseline | 1.69 (1.60–1.78) | <0.001 |
| Post‐baseline risk relative to baseline, comparator states | ||
| Early intervention period (6–9 wks.) | 0.73 (0.54–1.00) | 0.049 |
| Late intervention period (≥10 wks.) | 0.02 (0.01–0.04) | <0.001 |
| Additional decline in risk in MA relative to comparator states | ||
| Early intervention period | 0.47 (0.37–0.59) | <0.001 |
| Late intervention period | 0.80 (0.64–1.00) | 0.048 |
| SARS‐CoV‐2 Prevalence (standardized) | 2.32 (1.75–3.09) | <0.001 |
| Age (ref. 80–84 years old) | ||
| <65 | 1.05 (0.83–1.35) | 0.67 |
| 65–69 | 1.14 (0.97–1.34) | 0.12 |
| 70–74 | 1.14 (1.03–1.27) | 0.011 |
| 75–79 | 0.98 (0.89–1.09) | 0.75 |
| 85–89 | 0.80 (0.78–0.83) | <0.001 |
| ≥90 | 0.85 (0.79–0.92) | <0.001 |
| Female sex | 1.06 (0.96–1.17) | 0.23 |
| Race (ref. White) | ||
| Black | 1.80 (1.08–3.00) | 0.024 |
| Other | 1.20 (0.98–1.45) | 0.07 |
| ADL score (0–28) | 0.99 (0.98–0.99) | 0.013 |
| Dementia diagnosis | 1.31 (0.97–1.75) | 0.08 |
| Heart failure | 1.00 (0.87–1.17) | 0.95 |
| Coronary artery disease | 1.06 (1.04–1.08) | <0.001 |
| Asthma/COPD | 1.04 (0.95–1.12) | 0.46 |
| Chronic kidney disease | 0.98 (0.92–1.03) | 0.38 |
| Hypertension | 1.09 (0.98–1.21) | 0.12 |
| Diabetes | 1.07 (0.93–1.24) | 0.34 |
| Post‐acute patient | 0.51 (0.41–0.64) | <0.001 |
Note: Chronic kidney disease includes renal insufficiency, renal disease, or end‐stage renal disease. Massachusetts is being compared to New Hampshire, Rhode Island, and Connecticut, the reference group.
Abbreviations: ADL, activities of daily living; COPD, chronic obstructive pulmonary disease; MA, Massachusetts.
The coefficient on this variable represents the adjusted hazard of infection for Massachusetts residents relative to comparator state residents during the baseline period (1–5 weeks).
FIGURE 1Weekly risk of infection by study period. Model‐adjusted point estimates and 95% confidence intervals are displayed. The apparent effect attributable to the intervention is most evident during the early intervention phase (study weeks 6–9); during this 3‐week period the likelihood of infection declined more rapidly in Massachusetts than in the neighboring states. To 20 weeks, the cumulative decline in Massachusetts was likewise greater than in neighboring states, such that the greater likelihood of infection observed at baseline had largely been removed.